These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 11000340

  • 1. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA.
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [Abstract] [Full Text] [Related]

  • 2. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM, Adami S, Devogelaer JP, Chines AA.
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP.
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [Abstract] [Full Text] [Related]

  • 4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
    JAMA; 1999 Oct 13; 282(14):1344-52. PubMed ID: 10527181
    [Abstract] [Full Text] [Related]

  • 5. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
    Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.
    Osteoporos Int; 1997 Oct 13; 7(5):488-95. PubMed ID: 9425508
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 13; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 7. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 13; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 8. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC, Tong KH, To CH, Siu YP, Ma KM.
    Osteoporos Int; 2008 Mar 13; 19(3):357-64. PubMed ID: 18038273
    [Abstract] [Full Text] [Related]

  • 9. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
    Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP.
    Curr Med Res Opin; 2004 May 13; 20(5):757-64. PubMed ID: 15140343
    [Abstract] [Full Text] [Related]

  • 10. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
    Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD.
    J Clin Densitom; 2004 May 13; 7(3):255-61. PubMed ID: 15319494
    [Abstract] [Full Text] [Related]

  • 11. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH, Baylink DJ, Crusan CE, Chines AA.
    J Clin Endocrinol Metab; 2001 May 13; 86(5):1890-7. PubMed ID: 11344179
    [Abstract] [Full Text] [Related]

  • 12. Risedronate once a week.
    White NJ, Perry CM.
    Treat Endocrinol; 2003 May 13; 2(6):415-20; discussion 421. PubMed ID: 15981945
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 13; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec 13; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.